Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (72 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Bullboard (TSXV:TLT)

View:
Prev ... 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 ... Next
Post by m8magicon Sep 03, 2024 11:46am

willikers

 just get this company going...dang ronson lighter fluid will kill most viruses...we need someone some where to give this company money to take it upwards
407
Comment by O12009on Sep 03, 2024 11:20am

RE:No Money = No leverage

The problem with that of course is when and if your competition steps in and leaves you in their dust. A lot of life changing indications will be in the pipeline which will have major implications for ...more  
149
Discussion
Post by Gman620on Sep 03, 2024 11:06am

No Money = No leverage

If I'm a big pharma, I see a desperate company that is running out of money and time and has no leverage. I wait until they are on their last gasp, then swoop in and pick up the tech for pennies ...more  
544
Discussion
Post by Tarbabyon Sep 03, 2024 10:38am

PARTNER FOR VIRUS TREATMENT

Glaxo Smith Klien GSK markets Valcyclovir for herpes virus. They would be a natural partner for developing Ruvidar. Also why not for HPV also.as it can cause cancer.
437
Comment by Legit62on Sep 03, 2024 10:05am

RE:RE:RE:New Press Release - Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

Totally agree Oden6570, but nothing happens until we get BTD and AA IMO, lot of talk and showcasing but we are not derisked in FDA terms yet and until then just useless PRS ,again IMO. i want to hear ...more  
190
Discussion
Comment by Oden6570on Sep 03, 2024 9:45am

RE:RE:New Press Release - Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

The way I interpret recent announcements of which there have been many is Theralase is advertising with compelling results with many potential clinical implications and applications. It is my opinion ...more  
208
Discussion
Comment by Legit62on Sep 03, 2024 8:38am

RE:New Press Release - Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

"PreClinically", need to get to clincal stage before we start doing jumping jacks, and need financing before the cartwheels come, show me the money
147
Discussion
Post by Oden6570on Sep 03, 2024 7:54am

AI Bart suggests these dance partners :-)

Notice the heading of news release !!!!! Theralase® Technologies Inc. is currently seeking partnerships / licensing opportunities in the commercial development of this latest discovery ...more  
603
Comment by enriquesuaveon Sep 03, 2024 7:50am

RE:What is Dr Coombs current relationship with TLT ?

Beyond huge!  Most herpes infections are treated after infection where Acyclorir especially topical is very minimally effective.  Ruvidar has shown highly effective even a day after ...more  
203
Discussion
Post by Oden6570on Sep 03, 2024 7:43am

What is Dr Coombs current relationship with TLT ?

Kevin Coombs, B.A., M.A., Ph.D., professor at the Max Rady College of Medicine, Medical Microbiology and Infectious Diseases, University of Manitoba stated, " We previously demonstrated that ...more  
506
Discussion
Comment by Oilminerdeluxeon Sep 03, 2024 7:30am

RE:RE:RE:News Out !

One would think a partnership in this venture should not be too difficult to get done in a fairly quick time. This should fit Kaouthar Lbiati's skills perfectly. Make it happen asap please.
102
Discussion
Comment by Alamir1111on Sep 03, 2024 7:24am

RE:RE:News Out !

Sounds good  to me
66
Discussion
Comment by TimboBagginson Sep 03, 2024 7:22am

RE:RE:New Press Release - Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

  Did they just add sound as a method of activation or has that been mentioned before?
94
Discussion
Comment by Oden6570on Sep 03, 2024 7:19am

RE:RE:RE:News Out !

TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical ...more  
131
Discussion
Prev ... 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250